An artificial intelligence (AI) model created by integrating clinical, molecular, and histopathological data significantly improved recurrence risk stratification in hormone receptor (HR)-positive, HER2-negative breast cancer, ...
Dec 10, 2025
0
0
A new statistical tool that combines multiple clinical and pathologic factors with a patient's 21-gene Oncotype DX Breast Recurrence Score result provides more accurate estimates about that patient's breast cancer prognosis ...
Jan 24, 2025
0
0
A common test used to decide whether breast cancer patients should receive chemotherapy may be making bad recommendations for some Black women, leading them to forgo chemotherapy when it might have helped, according to new ...
Jan 29, 2024
0
0
Almost all postmenopausal patients aged 50-–69 years with stage I hormone receptor (HR)-positive breast cancer and low scores on a common genetic test who opted out of adjuvant radiotherapy were disease free five years ...
Dec 7, 2023
0
0
Patients with early-stage estrogen receptor-positive breast cancer who live in low-income neighborhoods are likelier to have more aggressive tumors and significantly lower overall survival (OS) than those in higher-income ...
Feb 21, 2023
0
109
Non-Hispanic Black women with hormone receptor (HR)-positive/HER2-negative, lymph node-positive breast cancer had worse outcomes compared to non-Hispanic whites, Asians, and Hispanics, despite similar 21-gene recurrence scores, ...
Dec 6, 2022
0
3
An analysis of data on the use of radiation therapy in a large clinical trial of patients with HR+, HER2- breast cancer who had one to three involved lymph nodes and a 21-gene recurrence score of 25 or less found that rates ...
Oct 24, 2022
0
17
